Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - A comparative bioavailability study of fish oil vs. krill oil

Zur Kurzanzeige

dc.identifier.uri http://dx.doi.org/10.15488/608
dc.identifier.uri http://www.repo.uni-hannover.de/handle/123456789/632
dc.contributor.author Schuchardt, Jan Philipp
dc.contributor.author Schneider, Inga
dc.contributor.author Meyer, Henrike
dc.contributor.author Neubronner, Juliane
dc.contributor.author Schacky, C. von
dc.contributor.author Hahn, Andreas
dc.date.accessioned 2016-11-02T08:33:43Z
dc.date.available 2016-11-02T08:33:43Z
dc.date.issued 2011
dc.identifier.citation Schuchardt, Jan Philipp; Schneider, Inga; Meyer, Henrike; Neubronner, Juliane; Von Schacky, C. et al.: Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - A comparative bioavailability study of fish oil vs. krill oil. In: Lipids in Health and Disease 10 (2011), 145. DOI: http://dx.doi.org/10.1186/1476-511X-10-145
dc.description.abstract Background: Bioavailability of omega-3 fatty acids (FA) depends on their chemical form. Superior bioavailability has been suggested for phospholipid (PL) bound omega-3 FA in krill oil, but identical doses of different chemical forms have not been compared. Methods. In a double-blinded crossover trial, we compared the uptake of three EPA+DHA formulations derived from fish oil (re-esterified triacylglycerides [rTAG], ethyl-esters [EE]) and krill oil (mainly PL). Changes of the FA compositions in plasma PL were used as a proxy for bioavailability. Twelve healthy young men (mean age 31 y) were randomized to 1680 mg EPA+DHA given either as rTAG, EE or krill oil. FA levels in plasma PL were analyzed pre-dose and 2, 4, 6, 8, 24, 48, and 72 h after capsule ingestion. Additionally, the proportion of free EPA and DHA in the applied supplements was analyzed. Results: The highest incorporation of EPA+DHA into plasma PL was provoked by krill oil (mean AUC 0-72 h: 80.03 34.71%*h), followed by fish oil rTAG (mean AUC 0-72 h: 59.78 36.75%*h) and EE (mean AUC 0-72 h: 47.53 38.42%*h). Due to high standard deviation values, there were no significant differences for DHA and the sum of EPA+DHA levels between the three treatments. However, a trend (p = 0.057) was observed for the differences in EPA bioavailability. Statistical pair-wise group comparison's revealed a trend (p = 0.086) between rTAG and krill oil. FA analysis of the supplements showed that the krill oil sample contained 22% of the total EPA amount as free EPA and 21% of the total DHA amount as free DHA, while the two fish oil samples did not contain any free FA. Conclusion: Further studies with a larger sample size carried out over a longer period are needed to substantiate our findings and to determine differences in EPA+DHA bioavailability between three common chemical forms of LC n-3 FA (rTAG, EE and krill oil). The unexpected high content of free EPA and DHA in krill oil, which might have a significant influence on the availability of EPA+DHA from krill oil, should be investigated in more depth and taken into consideration in future trials. eng
dc.language.iso eng
dc.publisher London : BioMed Central Ltd.
dc.relation.ispartofseries Lipids in Health and Disease 10 (2011)
dc.rights CC BY 2.0 Unported
dc.rights.uri https://creativecommons.org/licenses/by/2.0/
dc.subject absorption eng
dc.subject bioavailability eng
dc.subject ethyl esters eng
dc.subject fish oil eng
dc.subject krill oil eng
dc.subject re-esterified triacylglycerides eng
dc.subject uptake eng
dc.subject docosahexaenoic acid eng
dc.subject edible oil eng
dc.subject fish oil eng
dc.subject icosapentaenoic acid eng
dc.subject krill oil eng
dc.subject nko eng
dc.subject omega 3 fatty acid eng
dc.subject phospholipid eng
dc.subject unclassified drug eng
dc.subject docosahexaenoic acid eng
dc.subject fish oil eng
dc.subject icosapentaenoic acid eng
dc.subject phospholipid eng
dc.subject adult eng
dc.subject area under the curve eng
dc.subject article eng
dc.subject body weight eng
dc.subject controlled study eng
dc.subject crossover procedure eng
dc.subject diet supplementation eng
dc.subject double blind procedure eng
dc.subject drug bioavailability eng
dc.subject drug blood level eng
dc.subject drug formulation eng
dc.subject human eng
dc.subject human experiment eng
dc.subject intermethod comparison eng
dc.subject male eng
dc.subject maximum plasma concentration eng
dc.subject normal human eng
dc.subject phospholipid blood level eng
dc.subject randomized controlled trial eng
dc.subject time to maximum plasma concentration eng
dc.subject animal eng
dc.subject blood eng
dc.subject chemistry eng
dc.subject clinical trial eng
dc.subject comparative study eng
dc.subject controlled clinical trial eng
dc.subject Euphausiacea eng
dc.subject Euphausiacea eng
dc.subject Adult eng
dc.subject Animals eng
dc.subject Area Under Curve eng
dc.subject Chemistry, Pharmaceutical eng
dc.subject Docosahexaenoic Acids eng
dc.subject Double-Blind Method eng
dc.subject Eicosapentaenoic Acid eng
dc.subject Euphausiacea eng
dc.subject Fish Oils eng
dc.subject Humans eng
dc.subject Male eng
dc.subject Phospholipids eng
dc.subject.ddc 500 | Naturwissenschaften ger
dc.subject.ddc 570 | Biowissenschaften, Biologie ger
dc.title Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - A comparative bioavailability study of fish oil vs. krill oil
dc.type Article
dc.type Text
dc.relation.issn 1476-511X
dc.relation.doi http://dx.doi.org/10.1186/1476-511X-10-145
dc.bibliographicCitation.volume 10
dc.bibliographicCitation.firstPage 145
dc.description.version publishedVersion
tib.accessRights frei zug�nglich


Die Publikation erscheint in Sammlung(en):

Zur Kurzanzeige

 

Suche im Repositorium


Durchblättern

Mein Nutzer/innenkonto

Nutzungsstatistiken